Lupin Launches Generic Aciphex® Delayed-Release Tablets, 20 mg in the US

   Lupin Launches Generic Aciphex® Delayed-Release Tablets, 20 mg in the US

PR Newswire

MUMBAI and BALTIMORE, November 11, 2013

MUMBAI and BALTIMORE, November 11, 2013 /PRNewswire/ --

Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary,
Lupin Pharmaceuticals, Inc. (LPI) has launched its generic Rabeprazole Sodium
delayed-release tablets, 20mg. Lupin had earlier received final approval from
the US FDA for the same.

Lupin's Rabeprazole Sodium delayed-release tablets, 20mg, are the generic
equivalent of Eisai Inc.'s Aciphex® delayed-release tablets, 20mg, and are
indicated for the treatment of Gastroesophageal reflux disease (GERD).
Aciphex® delayed-release tablets, 20mg, had annual U.S sales of approximately
US$ 864.3 million (IMS MAT Jun 2013). 

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company producing and
developing a wide range of branded and generic formulations and APIs globally.
The Company is a significant player in the Cardiovascular, Diabetology,
Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global
leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US
(5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian
pharmaceutical company by sales. The Company is also the fastest growing top
10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin's Consolidated turnover and
Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142
million (USD 242 million) respectively. Please visit
for more information.

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated
to delivering high-quality, affordable generic medicines and branded
formulations trusted by healthcare professionals and patients across
geographies. For more information, visit 

For more information, please contact -

Shamsher Gorawara
Head - Corporate Communications
Ph: +91-98-20-338-555

Safe Harbor Statement
*ACIPHEX® is a registered trademark used by Eisai Inc.

SOURCE Lupin Ltd
Press spacebar to pause and continue. Press esc to stop.